The standard approach for relapsed diffuse large B-cell lymphoma (DLBCL) involves auto-SCT. However, studies that established this approach were conducted before the inclusion of rituximab (R) with first-line therapy became routine. Whether DLBCL patients (pts) relapsing after first-line chemoimmunotherapy including R derive a comparable benefit from auto-SCT to pts in the pre-R era is unknown. We analyzed outcomes after auto-SCT for relapsed DLBCL among pts receiving initial R and those who did not. We reviewed 257 consecutive pts with relapsed DLBCL treated at our institution with auto-SCT. In all, 226 pts were included in the analysis, of whom 161 had received no R and 65 received R as part of first-line therapy (Planned R). Median OS and relapse-free survival, measured from transplant, were similar between No R vs Planned R groups: 67 vs 44 months (P ¼ 0.3) and 25 vs 27 months (P ¼ 0.8), respectively. A further analysis was carried out between two cohorts matched by propensity analysis. Again, no differences in outcomes were observed. This suggests that auto-SCT may be equally effective in pts relapsing after first-line therapy including R, and should remain the standard of care for relapsed DLBCL.
Introduction
Diffuse large B-cell lymphoma (DLBCL) represents about one-third of all non-Hodgkin's lymphomas (NHL). 1 Until recently, CHOP (CY, doxorubicin, VCR and prednisone) was regarded as the standard first-line therapy. The addition of the anti-CD20 MoAb rituximab to combination chemotherapy improves response and survival rates in several subtypes of NHL including DLBCL, [2] [3] [4] [5] making CHOP þ rituximab chemoimmunotherapy the modern standard for treatment of this disease.
Nonetheless, a large proportion of patients with DLBCL (including half of the patients in high-risk groups) fail initial therapy. 5 These patients are generally recommended to undergo high-dose chemotherapy followed by auto-SCT. Auto-SCT has been the standard of care for relapsed, chemosensitive DLBCL following results from the PARMA trial published in 1995. 6, 7 This study demonstrated a superior OS for chemosensitive patients undergoing auto-SCT compared with those randomized to receive conventional chemotherapy. However, there remains a paucity of data regarding the potential influence of previous rituximab on outcomes after auto-SCT. As rituximab-based therapy is more effective than chemotherapy alone as first-line treatment of DLBCL, we postulated that patients who relapse after rituximab-containing therapy may represent a more adverse group than those relapsing after chemotherapy alone. Whether patients relapsing after first-line rituximab derive the same benefit from auto-SCT is therefore unclear, even though auto-SCT is commonly applied in this setting.
The purpose of this study was to review our single-center experience of the use of salvage auto-SCT in patients with relapsed DLBCL after first-line rituximab-containing regimens, and to compare the outcomes in this group with patients not previously receiving rituximab.
Patients and methods
This is a single institution retrospective analysis of consecutive DLBCL patients undergoing auto-SCT at the Cleveland Clinic Taussig Cancer Institute, performed with approval of our Institutional Review Board.
Patients
In all, 257 consecutive patients with relapsed DLBCL (as defined by the World Health Organization) undergoing auto-SCT from 1994 to 2004 were identified from our Unified Transplant Database. 8 Each case was confirmed by the central hematopathology review at the Cleveland Clinic Taussig Cancer Institute. Patients considered for transplant had acceptable cardiac and pulmonary function based on pre-transplant evaluation. PBSCs were mobilized using either filgrastim or high-dose etoposide and filgrastim according to our institutional protocol. Patients received a preparative regimen of BU (either 1 mg/kg orally or 0.8 mg/kg i.v. every 6 h for 14 doses), etoposide (60 mg/kg i.v. continuous infusion) and CY (60 mg/kg i.v. daily, for 2 consecutive days). Blood product support antibiotics and growth factors were given in accordance with institutional protocols.
Patients with available data were divided into three groups based on their history of treatment with rituximab. Group 1 included those patients who had not received rituximab (161 patients; No R), group 2 included those patients who received rituximab as part of first-line treatment (65 patients; Planned R) and group 3 consisted of patients who had received rituximab as a component of second-line salvage therapy before auto-SCT, but who had not received rituximab as part of first-line therapy (31 patients). To avoid the potentially confounding influence of rituximab used as salvage therapy and permit a simpler comparison, patients in group 3 were excluded from this analysis. This left 226 evaluable patients.
Statistical analysis
Categorical variables are summarized as frequency counts and percentages, and compared between No R and Planned R using the w 2 -test. Continuous variables are summarized as the mean or median and range, and compared between groups using either the t-test or Wilcoxon rank-sum test.
The primary end points were OS and relapse-free survival (RFS), calculated relative to transplant date. Outcomes were estimated using the Kaplan-Meier method and compared between No R and Planned R using the logrank test. Cox proportional hazards analysis was used to assess the effect of Rituxan after adjusting for variables, which differed between No R and Planned R or variables that were prognostic for OS or RFS.
As the No R and Planned R groups were not balanced with respect to pre-transplant characteristics, propensity matching was carried out to identify well-matched groups. The basic concept of propensity analysis is to identify two groups, which are similar with respect to known baseline characteristics and that differ only on the variable being assessed (in this case, rituximab exposure). 9, 10 Once the well-matched groups are identified, outcomes are compared between the two groups without adjustment for other factors. The probability that a patient received rituximab (propensity score) was calculated from a logistic regression model that included the following nine variables: age, gender, stage, number of previous chemotherapy regimens, previous radiation, months from diagnosis to transplant, disease status at transplant, international prognostic index (IPI) at transplant and CD34 þ dose. The propensity score was used to seek a match for each patient who had Planned R to one who had No R. This resulted in well-matched groups of 50 Planned R and 50 No R patients. Outcomes were estimated using the Kaplan-Meier method, and compared between the two groups using the log-rank test as described for the unmatched analysis.
Results

Patient characteristics
Patient characteristics of the 226 study patients are shown in Table 1 . Patients who received rituximab were older (P ¼ 0.02), had higher stage disease (P ¼ 0.05), were more likely to have received three or more previous chemotherapy regimens (Po0.001), had a greater number of CD34 þ cells infused (Po0.001) and had shorter follow-up (Po0.001) than those who had not received rituximab. Propensity analysis identified two groups of 50 patients in whom no differences in pre-transplant characteristics were observed in terms of age (P ¼ 0.6), stage (P ¼ 0.6), gender (P ¼ 0.5), number of previous regimens (P ¼ 0.5), previous radiation therapy (P ¼ 0.5), months from diagnosis to transplant (P ¼ 0.8), disease status at transplant (P ¼ 1.0), IPI at transplant (P ¼ 1.0) and CD34 þ cell dose (P ¼ 0.8).
Outcome and predictors of outcome Kaplan-Meier estimates of OS and RFS for the unmatched groups are shown in Figures 1 and 2 , and for the propensity-matched groups in Figures 3 and 4 . Median follow-up of survivors in No R group is 107 months and 61 in the Planned R group. Median survival in the No R and Planned R groups was 67 months vs 44 months, respectively (P ¼ 0.3). RFS in the No R group was 25 months vs 27 months in the Planned R group (P ¼ 0.8).
Univariate analysis showed that OS in the entire group was affected by age (hazards ratio (HR) per 10 year increase 1.4, Po0.001), number of previous regimens (HR per 1 regimen increase 1.4, Po0.001) and CD34 þ cell dose (HR for cell dose o4.9 Â 10 6 per kg vs 47.5 Â 10 6 per kg 1.7, P ¼ 0.02). Other characteristics, including timing relative to the first transplant in the series, did not affect OS (P ¼ 0.4).
Cox proportional hazards analysis was carried out to adjust for age, stage, number of previous regimens, disease status at transplant and CD34 dose. Survival and relapse outcomes after this adjustment were similar (P ¼ 0.3 for OS, P ¼ 0.5 for RFS). Likewise, outcomes were similar among the propensity-matched groups (P ¼ 0.5 for OS, P ¼ 0.9 for RFS; see Figures 3 and 4) .
Discussion
CHOP-R is now the standard front-line therapy for advanced DLBCL, based on the results of randomized trials including the landmark study carried out by GELA (Groupe d'Etude des Lymphomes de l'Adulte). This trial enrolled older patients (ages 60-80 years) with newly diagnosed DLBCL. Patients were randomly assigned to CHOP vs CHOP plus rituximab (CHOP-R) for a total of eight cycles. 2 A survival benefit was demonstrated with the rituximab-containing regimen (5-year OS of 58% in the CHOP-R arm and 45% in the CHOP arm). 3 Subsequent studies with younger patients confirmed the benefit of adding rituximab to chemotherapy as did a populationbased analysis to assess the impact of CHOP-R in adult patients. 4, 5 These studies have led to the ubiquitous use of rituximab chemoimmunotherapy in first-line treatment of DLBCL. 
The superiority of auto-SCT over conventional salvage chemotherapy for relapsed DLBCL was first demonstrated by the PARMA randomized trial. 6 Although still widely regarded as the standard approach for these patients, the relevance of this study to current management of relapsed DLBCL is uncertain. Eligibility to the PARMA study was restricted to patients aged o60 years, with a previous CR to first-line chemotherapy, and with no evidence of BM or central nervous system involvement by lymphoma. All patients in this study underwent BM harvest as the source of autologous stem cell support. In addition, the study was open to all patients with diffuse large-cell lymphoma according to the Working Formulation, which included histologies other than DLBCL. With the advent of improved supportive care, including the use of PBPC transplantation, auto-SCT is now applied to older patients and frequently to those with a history of marrow involvement. Many patients now offered auto-SCT may not have achieved a CR with initial therapy.
Moreover, we hypothesized that patients who fail firstline therapy including rituximab may represent an inherently adverse group. Preliminary results from the CORAL study support this assertion. This trial randomized patients with relapsed or refractory DLBCL to one of two common salvage chemoimmunotherapy regimens before auto-SCT, and found that patients with previous rituximab exposure had a significantly worse 3-year EFS and OS. 11 Published only in abstract form, details of patient characteristics and statistical procedures will be key to interpreting these findings. On the other hand, the results of our study suggest that high-dose therapy and auto-SCT is equally effective in patients previously treated with rituximab compared with those who have not.
Several considerations apply in interpreting our retrospective results. The conditioning regimen and transplant procedure at our institution did not change appreciably, and univariate analysis failed to show timing with regard to the first transplant had an impact on outcomes. Therefore, it is unlikely that the Planned R cohort benefited substantially from recent technologies or improvements in supportive care. However, such a benefit (or other differences between groups influencing outcomes) cannot be ruled out in this study design. In addition, although the cohorts were matched by propensity analysis with respect to known pre-transplant characteristics, biological parameters were not taken into account. DLBCL is heterogeneous with several variants distinguished by histological and molecular analyses. Several studies have identified biological parameters that seem to have prognostic significance independent of clinical prognostic factors. Expression of Bcl-6 has been associated with an improved OS independent of the IPI, whereas Bcl-2 expression and low expression of HLA-DR and CD10 correlated with inferior PFS. 12, 13 In our study, data were not available for cell of origin (determination of germinal B-cell vs nongerminal center phenotype), although it should be noted that several studies find similar outcomes between these groups after auto-SCT. [14] [15] [16] [17] Given the survival advantage previously described with CHOP-R therapy for advanced DLBCL, it is unlikely that a prospective randomized control trial of auto-SCT in relapsed DLBCL based on previous therapy will be carried out. The results of this retrospective analysis suggest benefit from auto-SCT in those patients who relapse despite first-line rituximab treatment. Taking this into account, the role of auto-SCT in relapsed DLBCL remains a reasonable standard of care. Outcomes after auto-SCT for DLBCL unaffected by previous rituximab SD Smith et al
